Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00099736 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplant
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 696
- Enrollment target
NCT00099736 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 696 participants.
The verdict
NCT00099736, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 696 participants
- Enrollment target
Study Summary
The efficacy and safety of FTY720 is being evaluated in patients who receive a kidney transplant.
Interventions
- DRUG FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids
- DRUG FTY720 2.5 mg + full dose Neoral (FDN) + corticosteroids
- DRUG MMF 2 g + full-dose Neoral (FDN) + corticosteroids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 696 participants |
| Start Date | 2003-05-07 |
| Est. Completion | 2005-09-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00099736
The ClinicalTrials.gov registry entry for NCT00099736 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 696 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids is the first listed.
NCT00099736 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00099736 about?
NCT00099736 is a clinical study titled "Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplant". The efficacy and safety of FTY720 is being evaluated in patients who receive a kidney transplant.
What is the current status of trial NCT00099736?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 696 participants. The study started on 2003-05-07. Estimated completion is 2005-09-19.
What interventions are being tested in trial NCT00099736?
The interventions under investigation include: FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids (DRUG), FTY720 2.5 mg + full dose Neoral (FDN) + corticosteroids (DRUG), MMF 2 g + full-dose Neoral (FDN) + corticosteroids (DRUG).
Who is sponsoring clinical trial NCT00099736?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.